Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Duane Reade revenues

This article was originally published in The Tan Sheet

Executive Summary

Same-store sales rise 3% for drugstore chain in second quarter ended Sept. 30. Overall sales of $338.6 mil. in period fall $11.4 mil. below company's previously issued expectations. Duane Reade 1cites Aug. 14 blackout for $3.3 mil. of sales loss, as well as Claritin and Prilosec Rx-to-OTC switches for slowing pharmacy growth. Firm lowers third quarter earnings expectations from 15¢ to 20¢ cents to 8¢ to 9¢ cents per share. "We are experiencing the impact of lower growth in our prescription sales resulting from pharmacy to over-the-counter conversions, reduced demand in certain areas, as well as an increase in the number of uninsured," CEO Anthony Cuti says Oct. 6...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS096037

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel